Recent Posts

• Rare Disease Heroes
• Valerion Initiates VAL-1221 Dosing in Patients with Pompe Disease
• Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study
• Valerion Reports Preclinical Potential for Pompe Treatment
• Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day